PSNL

Personalis, Inc. operates as a cancer genomics company that provides advanced genomic sequencing and data analysis services for precision oncology applications. Headquartered in Fremont, California, the company serves both biopharmaceutical organizations and clinical customers through its proprietary platforms. Personalis offers its NeXT Platform, which delivers comprehensive tumor and normal tissue profiling for therapy selection and clinical trial support, and its ImmunoID NeXT Platform, which analyzes the tumor microenvironment and immune response characteristics. The company's Population Sequencing division focuses on large-scale genomic initiatives and research programs. Personalis serves major pharmaceutical and biotech companies in their drug development efforts, particularly in immuno-oncology, while also supporting clinical diagnostics through its molecular tumor board services. The company has established partnerships with the U.S. Department of Veterans Affairs for the Million Veteran Program and maintains collaborations with leading cancer centers. In recent years, Personalis has expanded its laboratory capabilities and enhanced its bioinformatics platforms to improve turnaround times and data interpretation. The company employs approximately 400 people and operates CLIA-certified and CAP-accredited laboratories. Founded in 2011, Personalis went public in 2019 and continues to focus on advancing precision cancer medicine through comprehensive genomic profiling that encompasses DNA and RNA analysis from both tumor and normal tissue samples.